Novus Therapeutics Announces One-for-Eighteen Reverse Stock Split
02 Outubro 2020 - 12:00PM
Business Wire
Novus Therapeutics, Inc. (NASDAQ : NVUS) today announced that it
has filed a Certificate of Amendment to its Amended and Restated
Certificate of Incorporation to effect a reverse stock split of its
issued and outstanding common stock, at a ratio of 1-for-18. The
effective time of the reverse stock split will be 12:01 a.m.
(Eastern Time) on October 5, 2020. Novus common stock will begin
trading on a split-adjusted basis commencing upon market open on
October 5, 2020.
As a result of the reverse split, every 18 shares of Novus’s
issued and outstanding common stock will be automatically combined
and converted into one issued and outstanding share of common
stock, par value $0.001 per share. Novus’s common stock will
continue to trade on the Nasdaq Capital Market under the symbol
“NVUS,” but will be assigned a new CUSIP number, 67011N 204. The
reverse stock split reduces the number of shares of common stock
issuable upon the conversion of Novus’s outstanding preferred stock
and the exercise or vesting of its outstanding stock options,
restricted stock units and warrants in proportion to the ratio of
the reverse stock split and causes a proportionate increase in the
conversion and exercise prices of such convertible notes, stock
options and warrants.
No fractional shares of common stock will be issued as a result
of the reverse stock split. Stockholders of record who would
otherwise be entitled to receive a fractional share will receive a
cash payment in lieu thereof. The reverse stock split impacts all
holders of Novus’s common stock proportionally and will not impact
any stockholder’s percentage ownership of common stock (except to
the extent the reverse stock split results in any stockholder
owning only a fractional share).
Novus has appointed its transfer agent, Continental Stock
Transfer & Trust, to act as exchange agent for the reverse
stock split. Stockholders owning shares via a bank, broker or other
nominee will have their positions automatically adjusted to reflect
the reverse stock split and will not be required to take further
action in connection with the reverse stock split, subject to
brokers’ particular processes.
About Novus Therapeutics
Novus Therapeutics, Inc. is a clinical stage biotechnology
company using its expertise in targeting the CD40L pathway to
develop potential treatments for organ or cellular transplantation,
as well as for autoimmune and neurodegenerative diseases. Novus is
headquartered in Irvine, Calif. For more information, please visit
the company’s website at www.novustherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201002005351/en/
Amanda Sellers asellers@vergescientific.com 301.332.5574
Novus Therapeutics (NASDAQ:NVUS)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Novus Therapeutics (NASDAQ:NVUS)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Novus Therapeutics Inc da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Novus Therapeutics, Inc.